Search

Author/Creator Ananthakrishnan, Revathi

1. A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. (22nd April 2016)

Authors:
Goy, Andre; Forero, Andres; Wagner‐Johnston, Nina; Christopher Ehmann, W.; Tsai, Michaela; Hatake, Kiyohiko; Ananthakrishnan, Revathi; Volkert, Angela; Vandendries, Erik; Ogura, Michinori
Journal:
British journal of haematology
Issue:
Volume 174:Number 4(2016)
Page Start:
571
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. (1st January 2017)

Authors:
Sangha, Randeep; Davies, Andrew; Dang, Nam H.; Ogura, Michinori; MacDonald, David A.; Ananthakrishnan, Revathi; Paccagnella, M. Luisa; Vandendries, Erik; Boni, Joseph; Goh, Yeow Tee
Journal:
Journal of drug assessment
Issue:
Volume 6(2017)
Page Start:
10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma. (26th May 2022)

Authors:
Makita, Shinichi; Yamamoto, Go; Maruyama, Dai; Asano‐Mori, Yuki; Kaji, Daisuke; Ananthakrishnan, Revathi; Ogasawara, Ken; Stepan, Lara; Schusterbauer, Claudia; Rettby, Nils; Hasskarl, Jens; Izutsu, Koji
Journal:
Cancer medicine
Issue:
Volume 11:Number 24(2022)
Page Start:
4889
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗